CorMedix Inc. (CRMD) Stock Price & How to Invest
Last updated July 2026
Short answer
CorMedix (CRMD) is a newly commercial specialty pharma built around DefenCath, the first and only FDA-approved antimicrobial catheter lock solution, that has turned profitable fast and broadened into a hospital anti-infectives platform via the Melinta acquisition. It is a small-cap growth story whose whole thesis rests on continued DefenCath uptake and reimbursement, so it fits investors comfortable with single-product concentration and healthcare-policy risk.
CRMD stock price
As of 2026-07-20, CorMedix Inc. (CRMD) last closed at $7.78, down 28.9% over the past year. Over the past 52 weeks it has traded between $6.25 and $14.83.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or CorMedix Inc.'s investor relations page. Walnut is informational, not investment advice.
What does CorMedix Inc. (CRMD) do?
CorMedix is a New Jersey-based pharmaceutical company whose lead product, DefenCath (taurolidine and heparin), is the first and only FDA-approved antimicrobial catheter lock solution in the United States. It prevents catheter-related bloodstream infections in adult hemodialysis patients who use a central venous catheter, a population where infections drive costly hospitalizations and mortality, and a Phase III study showed up to a 71% reduction in infection risk. After a 2023 approval, commercialization scaled quickly through multi-year agreements that now cover roughly 60% of the U.S. outpatient dialysis market, and DefenCath generated about ~$167.6M in 2025 sales.
The investment picture shifted in 2025 when CorMedix acquired Melinta Therapeutics for ~$300M, adding six marketed infectious-disease products plus Toprol-XL and turning a single-product dialysis story into a broader institutional anti-infectives platform. The company is now solidly profitable and EBITDA-positive, with Q1 2026 revenue of ~$127.4M and net income of ~$38.6M, and it raised full-year 2026 guidance to ~$325M to $345M in revenue. The key debate is durability: how much of DefenCath's economics survive as early add-on reimbursement support (TDAPA) phases out, and whether Melinta and pipeline expansion can diversify away from heavy reliance on one drug.
What's driving CorMedix Inc. (CRMD)?
1. DefenCath adoption in outpatient dialysis
DefenCath is the only FDA-approved antimicrobial catheter lock solution, and CorMedix has signed multi-year agreements reaching roughly 60% of the U.S. outpatient dialysis market. Continued utilization gains within contracted providers, plus real-world evidence supporting infection reduction, are the primary revenue engine.
2. Melinta platform diversification
The ~$300M Melinta acquisition added six marketed hospital anti-infectives and Toprol-XL, contributing ~$29.9M in Q1 2026. This widens CorMedix's reach into hospitals and infusion settings and is the main lever for reducing single-product concentration.
3. Profitability and self-funding growth
CorMedix has reached net income and adjusted EBITDA profitability unusually early for a small-cap pharma, reporting ~$70M adjusted EBITDA in Q1 2026. Positive cash generation gives it flexibility to fund the pipeline, integrate Melinta, and pursue further business development without heavy dilution.
4. Label and pipeline expansion
Beyond the core hemodialysis indication, CorMedix has discussed extending DefenCath and its anti-infective platform into adjacent patient populations and settings. Additional indications or new products would lengthen the growth runway and support the higher end of guidance.
What are the risks to CorMedix Inc. (CRMD)?
Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. The product benefited from early reimbursement support such as the Transitional Drug Add-On Payment (TDAPA), and those benefits are expiring, which could pressure pricing and margins as dialysis reimbursement normalizes. Competition is a latent threat: established players such as Amphastar could extend anticoagulant or lock-solution capabilities into the catheter-infection market. The Melinta portfolio carries integration risk and includes mature products with their own competitive and reimbursement dynamics. As a small-cap healthcare name, the shares are volatile and sensitive to policy, payer, and single-quarter execution swings.
How is CorMedix Inc. (CRMD) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CorMedix Inc.'s investor relations page or your broker.
- Q1 2026 Revenue: ~$127.4M
- FY2026 Revenue Guidance: ~$325M-$345M
- Q1 2026 Net Income: ~$38.6M
- Q1 2026 Adjusted EBITDA: ~$70M
- Market Cap: ~$650M
- Analyst Avg Price Target: ~$14.5
CorMedix trades at a modest revenue multiple relative to many pre-profit biotech peers because it is already GAAP-profitable and EBITDA-positive, an unusual combination for a company only a couple of years into commercialization. Sell-side coverage skews constructive with an average 12-month target around ~$14.5, though price targets have drifted (for example RBC trimmed to ~$13 in mid-2026). The valuation debate centers on how durable DefenCath economics are once early reimbursement support fully rolls off.
Who competes with CorMedix Inc. (CRMD)?
Catheter lock and infection-prevention approaches
DefenCath currently has no directly approved U.S. rival as the first and only antimicrobial catheter lock solution, but it competes against standard-of-care heparin or saline locks and antibiotic-lock practices. The main forward risk is a large manufacturer such as Amphastar extending its anticoagulant footprint into the catheter-related bloodstream infection market.
Hospital anti-infectives (Melinta portfolio peers)
Through the Melinta products, CorMedix now competes in institutional anti-infectives against larger specialty and branded/generic pharma companies (for example Merck, Pfizer, and Basilea-type niche infectious-disease players) that market antibiotics and antifungals to hospitals and infusion providers.
Small-cap commercial specialty pharma
As an investment, CRMD sits among newly commercial small-cap specialty pharma names where the thesis rests on one or two products scaling; peers in that bucket share similar concentration, reimbursement, and volatility characteristics rather than direct product overlap.
How to invest in CorMedix Inc. (CRMD)
There are three common ways to get CRMD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CRMD sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where CRMD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on CorMedix Inc. (CRMD)
CRMD is a rare profitable micro/small-cap pharma riding one breakout product, and the payoff hinges on DefenCath adoption holding up as its early reimbursement tailwind fades.
More on CorMedix Inc. (CRMD)
Whether CRMD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRMD a buy?, and where the stock could go from here in the CRMD stock forecast.
For income investors, whether CRMD pays a dividend and how the payout looks is covered in does CRMD pay a dividend?
Build a basket around CRMD with Walnut
Use CorMedix Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does CorMedix (CRMD) do?
+
CorMedix is a specialty pharmaceutical company whose lead product, DefenCath, is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., used to prevent catheter-related bloodstream infections in hemodialysis patients. Following the 2025 Melinta acquisition it also markets a portfolio of hospital anti-infective products.
Is CorMedix profitable?
+
Yes. As of July 2026 CorMedix is profitable on both a net-income and adjusted-EBITDA basis, reporting roughly ~$38.6M of net income and ~$70M of adjusted EBITDA on ~$127.4M of revenue in Q1 2026, which is unusual for a company only recently commercial.
What is DefenCath and why does it matter?
+
DefenCath (taurolidine and heparin) is an antimicrobial lock solution instilled into central venous catheters used for hemodialysis. In a Phase III study it reduced catheter-related bloodstream infection risk by up to 71%, addressing a costly and dangerous complication, and it is the only FDA-approved product in its class.
How big is CorMedix's revenue?
+
CorMedix guided to roughly ~$325M to $345M of net revenue for full-year 2026 after Q1 2026 revenue of ~$127.4M. DefenCath generated about ~$167.6M in 2025, and the acquired Melinta portfolio adds well over $100M in annualized revenue.
What are the main risks to CorMedix stock?
+
The biggest risks are concentration in DefenCath, the expiration of early reimbursement support such as TDAPA, potential future competition in catheter infection prevention, and integration risk from the Melinta acquisition. As a small-cap healthcare name the shares are also quite volatile.
Why did CorMedix acquire Melinta Therapeutics?
+
CorMedix acquired Melinta for about ~$300M in 2025 to diversify beyond DefenCath. The deal added six marketed infectious-disease products plus Toprol-XL and expanded its reach into hospitals and infusion settings, turning a single-product dialysis story into a broader anti-infectives platform.
How long is DefenCath protected by patents?
+
DefenCath carries patent protection into the early 2030s, and CorMedix has announced additional issued patents extending intellectual-property coverage as far as 2042, which supports the durability of its exclusivity in the catheter lock solution space.
How can I invest in CorMedix through Walnut?
+
CRMD trades on the Nasdaq, so you can research it and add it to a thematic basket in Walnut alongside other healthcare or specialty-pharma names, then place orders through your connected brokerage. Walnut is not an investment adviser, and any position should reflect your own goals and risk tolerance.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with CorMedix Inc.'s investor relations page or your broker before making investment decisions.